- Open Access
Health survey of adults with hereditary spastic paraparesis compared to population study controls
© The Author(s). 2016
- Received: 29 March 2016
- Accepted: 15 June 2016
- Published: 13 July 2016
Hereditary spastic paraparesis (HSP) is a rare neurodegenerative condition characterized by slowly progressive spastic weakness of the lower limbs and urinary sphincter dysfunction. Complex HSP involves additional neurologic symptoms and signs like ataxia, extra pyramidal signs, polyneuropathy, and cognitive decline. Little is known about the disease burden for adults with HSP beyond the described core symptoms.
A cross-sectional survey of 108 adults aged 30 years and older (Mage = 57.7 years, SD = 11.5, range 30 to 81; 54.2 % females) recruited from a national center of expertise for rare disorders and a patient advocacy organization in Norway. Self-report data from the HSP sample was compared to self-report data from a large Norwegian population study, HUNT3 (N = 46,293), covering health-related variables such as overall life satisfaction, mental wellbeing, memory function, perceived pain, and co-morbid diseases. In addition, the HSP sample reported specific items developed for this study in co-operation with the patient advocacy organization.
The HSP sample more frequently lived alone. Overall, the HSP sample reported lower life satisfaction, lower mental wellbeing and lower social support, as well as poorer memory and sleep, compared to controls. Furthermore, the HSP sample more frequently reported musculoskeletal pain, constipation, and urinary incontinence compared to controls. There was no difference between samples in frequency of physical activity and alcohol and tobacco use. Men with HSP reported higher impact of HSP, lower life satisfaction, and less ability to perform activities of daily living compared to women with HSP.
Adults with HSP experience disease burden on a larger number of areas than previously documented, and men with HSP may represent a particularly vulnerable group.
- Life Satisfaction
- Mental Wellbeing
- Gastrointestinal Problem
- Lower Life Satisfaction
- Hereditary Ataxia
The term hereditary spastic paraparesis (HSP) is used to describe a group of neurodegenerative conditions with a high degree of clinical and genetic heterogeneity . HSP can be divided into “pure” and “complex” forms [1, 2]. Pure forms are characterized by slowly progressive spastic weakness in the lower limbs, and urinary sphincter dysfunction. In complex HSP, an additional wide range of neurological features including ataxia, extra pyramidal signs, epilepsy, mental retardation, dementia, and peripheral nerve involvement occurs . In pure HSP, lifespan is not affected . Early disease debut is most often associated with slow progression of the disease, with only a small proportion of affected persons reporting wheelchair use in older age. Late onset, however, tends to imply rapid progression and loss of walking ability from around the age of 60 years and onwards [2, 4, 5].
Several modes of inheritance of HSP have been described, both autosomal dominant, recessive, X linked, or maternal . Pure HSP is mostly inherited in an autosomal dominant manner, whereas complicated forms of HSP tend to be inherited in an autosomal recessive manner . To date, 59 different spastic paraplegia genes are known . Prevalence, based on studies from 16 countries, is estimated to be about 1.8:100 000 . In Norway, where the current survey took place, the estimated combined prevalence of pure and complex HSP has been reported to be 7.4:100 000 .
Bladder dysfunction has been described in older adults with HSP [11–13]. A handful of studies have shown disease progression correlates with more severe cognitive impairment [14–17]. The various medical issues that may affect persons with HSP could influence their perceived quality of life (QoL), as well as their psychological and social functioning. Although it is well documented that physical disease, including neurodegenerative disorders, impacts quality of life [18, 19], little is known about the quality of different areas of life for persons affected by HSP. Three studies have investigated QoL and/or psychosocial functioning in adults affected by HSP. In an Estonian study, QoL was found to be significantly lower in 49 persons with HSP aged 20 to 70 years compared to 549 healthy controls, except for the mental health domain . This study did not distinguish between pure and complex forms of HSP. In a German study, physical aspects of health-related QoL were more severely affected than mental aspects in a sample of 143 HSP patients with a mean age of 48 years. However, both spasticity and reduced mobility was associated with lower physical and mental scores. Complex HSP and disease severity predicted lower QoL. Furthermore, both physical and mental scores were lower in patients with complex HSP than in those with pure HSP . In a Brazilian study of 30 HSP patients with the SPG4 gene mutation and a mean age of 48 years, HSP patients reported more depression, pain, and fatigue compared to healthy controls .
Beyond these presented findings, there has been limited scientific effort to identify the range of symptoms that may affect persons with HSP. The present study is a broad survey of health and everyday life domains among persons with HSP, including life satisfaction, mental wellbeing, social support, problems with sleep, memory, pain, gastrointestinal/urinary functioning, and ability to perform activities of daily living (ADL). We applied five methodological features to increase interpretability of our findings. First, we recruited a large sample of persons with HSP to increase generalizability to the general HSP population. Second, we recruited our sample through a patient advocacy organization and a resource center for rare disorders, and not from a hospital setting, thereby increasing chances of also examining individuals with fewer symptoms. Third, we developed areas of investigation in co-operation with board members from a HSP patient advocacy organization to target our examination to symptom areas relevant for persons with HSP. Fourth, we applied a number of health-related questions drawn from a large population study, to compare our HSP data to those from a population-based control group. Fifth, we examined potential differences in the HSP sample based on patient age, gender, and pure versus complex HSP.
Sample and procedures
The sample comprised 108 persons with HSP recruited from two sources. The majority (61 %) was recruited from the register of The National Patients’ Association for Hereditary Ataxia and Spastic Paraplegia (NASPA). The remaining sample (39 %) was recruited from the database of Frambu Resource Centre for Rare Disorders (Frambu). Frambu is one of nine state-financed centers of expertise administrated by the Norwegian National Advisory Unit on Rare Disorders. Registration in Frambu’s patient database is voluntary and based on patient consent, and does not require medical referral. Diagnostic confirmation from a medical institution is required to be registered. Questionnaires with prepaid postage were initially sent to the 60 persons with HSP aged 30 years or older who were registered in Frambu’s database. Four weeks later, the questionnaire was sent to 235 NASPA members.
Population data from the third wave of the epidemiological survey “Helseundersøkelsen i Nord-Trøndelag” (HUNT3) was used as control group. HUNT3 is a comprehensive Norwegian survey of health conditions. All inhabitants in Nord-Trøndelag County aged 19 years and above were mailed questionnaires and an invitation to a clinical examination. HUNT3 (2006–2008) comprises the latest population data, providing recent results for gender and age groups comparable to our respondents. The control group comprised 46,293 persons, i.e., all participants aged 30 years and older from the third wave of HUNT3.
The HSP and control samples were not matched beyond age and gender, to examine differences in demographic variables between the HSP sample and controls (e.g., marital and educational status). The study was planned and performed in cooperation with NASPA and approved by The Regional Committee for Medical and Health Research (REK East).
The questionnaire comprised three main parts: (a) background and demographic information; (b) health-related questions specific to the HSP diagnosis; and (c) excerpts from HUNT3, covering several themes in relation to mental and physical health and functioning (i.e., life satisfaction, mental wellbeing, pain, sleep, diseases, oral health, gastrointestinal problems, medication use, physical activity, frequency of falling, social support, as well as health service use and satisfaction).
Most themes were covered by a few categorical questions best reported as frequencies rather than as scales. The sleep problems scale had unsatisfactory inter-item reliability, and the items were thus considered separately. We computed combined scale variables with satisfactory inter-item reliability for three themes (Mental wellbeing, α = .79; Memory, α = .88; Gastrointestinal problems, α = .67). Furthermore, we computed a Total physical impact variable by adding participants’ scores (No impact to Major impact) on the 11 symptoms, representing a 12 to 36-range scale from lowest to highest impact.
HSP-specific questions were compiled by the authors on the basis of current medical knowledge on HSP, in co-operation with board members of NASPA. Four board members of NASPA provided feedback on a preliminary version of the questionnaire. This feedback influenced selection of both HSP-specific questions and HUNT3 variables. In co-operation with NASPA we decided not to include questions on typical symptoms of complex HSP, to reduce the burden on participants. Controls were not presented with the HSP-specific questions.
Data were analyzed using IBM SPSS version 21.0. Comparisons between the HSP sample and controls were done by calculating Pearson’s chi-square to estimate whether frequencies were significantly different between the samples. To reduce expected frequencies below 5, some response categories were combined for some variables (e.g., often and very often) when required. When relevant, effect size differences were calculated as MHSP sample - Mcontrols/pooled standard deviation. We used the following cut off values to interpret magnitude of effect sizes: d = 0.2 (small), d = 0.5 (medium), and d = 0.8 (large) . Effect sizes were only calculated if differences were significant at or below the p = .05-level.
The response rate from patients in the Frambu database was 80 %. The exact response rate from the NASPA register is not known, as NASPA also has members with hereditary ataxias, who were asked to ignore the request. The response rate in HUNT3 was 54 %.
Comparison of samples
The mean age between the HSP sample and controls was comparable (M HSP = 57.7 years, SD = 11.5 vs. M controls = 55.9 years, SD = 14.0, d = 0.13). The gender distribution between the HSP sample and controls was not significantly different (female ratio HSP = 53.7 % vs. female ratio controls = 54.2 %; (χ 2 (1) = 0.011, p = .916).
Within the HSP sample, participants recruited from NASPA were significantly older than participants recruited from Frambu (M NASPA = 59.7 years, SD = 11.5 vs. M Frambu = 54.6 years, SD = 10.9, d = 0.46). The gender distribution was not significantly different dependent on recruitment setting (female ratio NASPA = 50.8 % vs. female ratio Frambu = 59.5 %; (χ 2 (1) = 0.788, p = .354).
Background variables for the HSP sample
(N = 107a)
(N = 49)
(N = 58)
<3years University degree
>3years University degree
Main source of income
Body mass index (BMI)
M = 25.5 (SD = 4.5)
M = 26.2 (SD = 4.0)
M = 24.9 (SD = 4.8)
HSP compared to controls
Comparing the HSP sample to controls, there were significant differences in family status (χ 2 (3) = 1711.46, p < .001). Participants in the HSP sample less frequently lived with a partner/spouse (χ 2 (1) = 5.37, p < .05), and more frequently lived alone (χ 2 (1) = 32.07, p < .001). There was no difference between the samples in frequency of living with parents (χ 2 (1) = 0.21, p = .647) or children (χ 2 (1) = 0.51, p = .477).
HSP sample compared to controls: Overview of main results
Main finding HSP sample
HSP sample compared to controls
Overall life satisfaction
M = 3.6 (SD = 1.2, range 1 to 7)a
HSP sample poorer (χ 2 (1) = 210.20, p < .001).
M = 11.4 (SD = 3.3, range 6 to 21)
HSP scored lower than controls on 5 of 6 items (χ 2 (1) range 13.38 to 65.95, all p < .001).
M = 15.2 (SD = 4.0, range 9 to 27)
HSP more frequently reported problems on 6 of 9 items (χ 2 (1) range 4.21 to 26.306, all p < .05)
Percentage of participants who rated several times a week: daytime drowsiness: 35 %; frequent night awakenings 36 %; trouble falling asleep 28 %; waking up early 19 %.
HSP reported more sleep problems on all items (χ 2 (1) range 6.39 to 59.26, all p < .05).
70 participants (64.8 %) confirmed chronic pain of >3 months duration in the past year. Most frequent pain sites: feet, knees, lower back, and hips.
HSP confirmed more frequent musculoskeletal pain (χ 2 (1) = 6.51, p < .05). HSP confirmed more frequent pain in the lower body pain sites (χ 2 (1) range 5.067 to 61.636, all p < .05). Controls more frequent pain in the upper body pain sites (χ 2 (1) range 7.817 to 26.141, all p < .05).
Comorbid disease prevalence
Most frequently reported diseases were mental health problems 19 %; osteoarthritis 14 %; hand eczema 11 %; psoriasis 10 %; asthma 8 %; and brain hemorrhage 7 %.
HSP more frequently reported brain hemorrhage (χ 2 (1) = 5.284, p < .05) and psoriasis (χ 2 (1) = 4.324, p < .05).
Percentage of participants who reported much problems: constipation 14 %; alternating constipation and diarrhea 7 %; bloating 7 %; heartburn 6 %; diarrhea; and nausea 0 %. 11 % confirmed fecal incontinence weekly or daily.
HSP more frequently reported much problems on alternating constipation and diarrhea (χ 2 (1) = 9.163, p < .05) and constipation (χ 2 (1) = 11.032, p < .05). HSP more frequently reported fecal incontinence (χ 2 (1) = 26.253, p < .001).
52 % confirmed urinary incontinence
HSP more frequently reported urinary incontinence (χ 2 (1) = 5.427, p < .05)
67 % rated their oral health as good or very good, while 13 % rated their oral health as poor or very poor.
No difference, but HSP reported more frequent dental visits during the last year compared to controls (χ 2 (1) = 4.466, p < .05).
Reported frequency of physical activity: daily 18 %; 2–3 times pr. week 33 %; once a week 22 %; less than once a week 14 %; and never 11 %.b
No difference in frequency. HSP spent more hours sitting daily compared to controls (MHSP = 9.0 vs. Mcontrols = 5.7, effect size difference d = 1.18).
Percentage of participants who reported taking nonprescription medicines 1–3 times weekly: for general pain 31 %; for constipation 17 %; for headache 16 %; and for heartburn 10 %.c
HSP more frequently reported taking medication for constipation (χ 2 (1) = 30.685, p < .001) and general pain (χ 2 (1) = 4.068, p < .05). Otherwise no difference.
Alcohol and tobacco use
Percentage of participants who reported drinking alcohol at least 2–3 times pr. week 20 %, never drinking alcohol 11 %, smoking daily 11 %.
Percentage of participants who confirmed practical support 82 % and emotional support 80 %d
HSP reported lower practical support (χ 2 (1) = 36.07, p < .001) and lower emotional support (χ 2 (1) = 13.59, p < .001).
The majority (58 %) reported that HSP was genetically confirmed. A quarter (24 %) reported that this was not the case, while 16 % reported they did not know. The majority (66 %) reported that one or more family members also had HSP. With multiple categories possible, the most frequently reported family members with HSP were siblings (n = 35), mothers (n = 25), children (n = 22), and fathers (n = 19).
Overall impact of HSP
Participants rated the overall impact of having HSP on a scale from 0 to 10, with 10 indicating the most negative impact. The mean rating was 7.2 (SD = 2.2), with males (m) rating a higher overall negative impact than females (f) (M m = 7.8, SD m = 2.1; M f = 6.7, SD f = 2.3; t = 2.399, p < .05; d = 0.50). The correlation between age and HSP impact was non-significant (r = .15, ns).
The mean score for all participants on the 12–36 range physical impact scale was 24.0 (SD = 4.8). There was no significant gender difference (M m = 24.7, SD m = 5.2; M f = 23.4, SD f = 4.4; t = 1.447, ns). Forty-two women responded to whether physical symptoms got worse with menstruation (including in retrospect for those beyond menstrual age). Of these 42 women, eight confirmed a low degree of worsening, three confirmed high degree of worsening, while 31 rated no worsening.
Mobility and activities of daily living
Ability to perform activities of daily living among 108 persons with HSP
Percentage who confirmed not being able to perform activity without assistance
N = 108
N = 75
N = 32
Walking indoors, ground floor
Visit the toilet
Get out of bed/get into bed
Preparing warm meals
Easy household chores
Complex household chores
Do the laundry
Getting outside daily
Taking the bus
We computed a total activities of daily living (ADL) score by adding the number of activities participants reported not being able to perform. The mean score was 2.7 activities, (SD = 3.6, range 0 to 16). Men reported more activities they could not perform without assistance compared to women (M m = 3.5, SD m = 4.3; M f = 2.0, SD f = 2.9; t = 2.101, p < .05; d = 0.16). Fisher’s exact tests showed that the two activities men reported to be able to perform less frequently compared to women were simple household chores (p < .05) and laundry (p < .001).
Frequency of falling
In the HSP sample, 47 % reported to have fallen in the last 3 months. There was no gender difference in frequency of falling (χ 2 (1) = 1.375, ns). There were no significant age difference between those who confirmed having fallen and those who did not (t = 0.588, ns).
HSP sample medication use
In the HSP sample, 15 % reported using Botox injections, 10 % reported using a baclofen pump, and 33 % reported taking oral spasmolytics. Of these, the percentages of participants reporting having some or large effect of the medication were 83 % for Botox, 86 % for baclofen pump, and 82 % for oral spasmolytics.
Gender differences within the HSP sample
There were no significant gender differences on any of the variables shown in Table 2, except overall life satisfaction. Males rated significantly lower life satisfaction compared to females (M m = 3.9, SD = 1.1, M f = 3.3, SD f = 1.3; t = −2.157, p < .05; d = 0.40).
Pure versus complex HSP
The majority of the HSP sample (69 %) reported to be “mainly affected in the lower body”, which was used a proxy for pure HSP. We examined whether there were significant differences based on this distinction, and found that this was the case for three variables. Participants with proxy complex HSP reported a higher overall impact of HSP (M pure = 6.9, SD pure = 2.1 vs. M complex = 8.1, SD complex = 2.3; t = 2.669, p <. 05; d = 0.55). Furthermore, those with proxy complex HSP were diagnosed at a later age compared to those with proxy pure HSP (M pure = 40.4 years, SD pure = 15.8 vs. M complex = 48.7 years, SD complex = 15.4; t = 2.435, p <. 05; d = 0.51). Finally, those with proxy complex HSP reported more ADL that they were not able to perform without assistance (M pure = 1.9 activities, SD pure = 2.9 vs. M complex = 4.4 activities, SD complex = 4.0; t = 3.439, p <. 001; d = 0.74). Significantly fewer participants with proxy complex HSP reported to have a driver license compared to those with proxy pure HSP (χ 2 (1) = 15.867, p < .001). See Table 3 for differences between the pure and complex types in terms of ability to perform activities of daily living.
There was no difference between the proxy pure/complex types in terms of age, total body impact, pain, mental well-being, memory, gastrointestinal/urinary problems, number of additional diseases, BMI, or physical activity.
Correlations between variables in the HSP sample
Correlations between variables among 108 adults with HSP
2. Age of onset
5. Overall HSP impacta
6. Physical impacta
7. Mental wellbeing
8. Life satisfactiona
9. Physical activity
10. Memory problemsa
11. Gastrointestinal problemsa
12. Number of diseases
14. Activities of daily livinga
The present report is a comprehensive survey of multiple health variables in a large sample of adults aged 30 years and older with HSP. Several variables were drawn from HUNT3, a large population survey, allowing comparison of results from the HSP sample to population controls. Compared to controls, persons with HSP reported lower scores on life satisfaction, mental wellbeing, as well as perceived practical and emotional support. Furthermore, compared to controls, persons with HSP reported more problems with memory, sleep, gastrointestinal and urinary function, and pain in the lower body. Our results showed persons with HSP experience large total physical impact of their disorder. This total impact was significantly correlated with age, mental wellbeing, memory problems, gastrointestinal problems, extent of pain, number of co-morbid diseases, and life satisfaction. Thus, the disease burden for adults with HSP is multifaceted, and involves problem areas not previously documented.
Gastrointestinal problems for persons with HSP have previously been documented in a Dutch study, in which combined fecal and urinary incontinence was identified among seven of 18 patients aged 13 to 46 years with complex HSP, specifically SPG11 mutation . In our HSP sample, gastrointestinal problems were significantly correlated with perceived quality of life. This in line with findings from a review of adult patients with central neurological disorders like Parkinson’s disease, Alzheimer’s disease and multiple sclerosis, in which impaired bowel function was shown to increase anxiety and reduce quality of life in . The identified gastrointestinal problems for persons with HSP warrant further research and clinical attention.
Our results also showed considerable impact on activities of daily living for persons with HSP. Over half the sample reported not being able to take the bus, and nearly half the sample reported not being able to do more than basic house chores. We were surprised to find that age was only correlated with total physical impact and ability to perform ADL, and not with any other health-related variable. This implies that the burden of disease experienced by adults with HSP is considerable across the lifespan. Importantly, older participants reported less practical support compared to younger participants, possibly indicating a particular need for the older HSP group.
We uncovered some important gender differences within the HSP sample. Specifically, men reported significantly higher overall impact of HSP, higher impact on sexual function, more ADL they could not perform without assistance, and lower overall life satisfaction compared to women with HSP. Possibly, the features of HSP are in larger conflict with typical gender expectations for men compared to women, as the stereotypical and traditional Western male gender role ideologies tend to favor physical capabilities as well as personal autonomy . On the other hand, we did not find gender differences that could be expected based on previous findings, such as in terms of perceived social support, which has been shown to be lower among males . In sum, our results indicate that men with HSP represent a particularly vulnerable group in terms of overall HSP impact and quality of life.
The current study has some limitations. First, we rely on self-reported diagnosis and not genetic confirmation. Although we have no reason to believe non-HSP patients responded, we cannot rule out this possibility. Second, beyond self-reported memory problems we did not assess cognitive abilities among participants. Cognitive deficits are documented among HSP patients and may impact both symptoms and self-report accuracy. Third, relying on self-report excluded possibilities of cross-referencing and validating data with medical records. Fourth, we used “only lower body affect” as a proxy for pure HSP. In a questionnaire-based study, this was perceived to be the most reliable distinction between pure and complex. The prevalence of the two forms in our study is in accordance with a previous survey . However, the validity of this distinction is uncertain, so our findings regarding differences between pure and complex HSP should be interpreted with caution. Finally, it is likely that some persons in the control group experience neuromotor problems, but due to the substantial size of the control group this is unlikely to have influenced results.
In spite of these limitations, the considerable sample size, the inclusion of a large population-based control group, and the involvement of a patient advocacy organization in the development of measures, indicate the results of the present report represent important and relevant insights into self-perceived functioning in patients with HSP. Future studies should examine the perspective of the providers of health services to patients with HSP, to identify potential knowledge gaps about this patient population.
The main clinical implications of the present report are that HSP patients should be assessed on a wide range of areas of functioning. Men with HSP and persons with complex HSP may be in particular need of such intervention. Mental health was significantly correlated with physical impact and overall impact of HSP. Although our design prevents us from examining causality, health professionals should also assess mental health in patients with HSP. Future studies should examine longitudinal development of the problem areas identified for patients with HSP, to provide better standards for care.
ADL, activities of daily living; HSP, hereditary spastic paraparesis; HUNT3, helseundersøkelsen i Nord-Trøndelag (Health Survey of Nord-Trøndelag); M, mean; NASPA, the national patients’ association for hereditary ataxia and spastic paraplegia; QoL, quality of life; SD, standard deviation
We express our sincere gratitude to the persons with HSP and controls who participated in this study. We also thank the board of the Norwegian Patients’ Association for Hereditary Ataxia and Spastic Paraplegia (NASPA) for their input to the study, including piloting the questionnaires, recruiting participants, and discussing the results. Finally, we thank Dr. Chantal Tallaksen at Oslo University Hospital for reading the manuscript and discussing the results with us.
The study was funded by Frambu resource centre for rare disorders.
Availability of data and materials
Data will not be generally shared. The data are subject to further scientific analyses that may be published in the future. Requests for data can be sent to the first author firstname.lastname@example.org and requests may be met depending on intent.
KF – planning and design, performing the statistical analyses, interpreting the data, drafting the methods, results and discussion sections, and revising the manuscript. OK – planning and design, data processing, interpreting the data, drafting the introduction, and revising the manuscript. EEN – planning and design, interpreting the data, and revising the manuscript. LBH – planning and design, data collection, interpreting the data, and revising the manuscript. GH –nitiating and planning the study, design, interpreting the data, drafting the introduction, and revising the manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
The study was approved by The Regional Committee for Medical and Health Research (REK East; project number 2013/2293-5). All participants were adults who consented to participate with written informed consent.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Salinas S, Proukakis C, Crosby A, Warner TT. Hereditary spastic paraplegia: clinical features and pathogenetic mechanisms. Lancet Neurol. 2008;7(12):1127–38.View ArticlePubMedGoogle Scholar
- Harding AE. Hereditary ‷pure” spastic paraplegia: a clinical and genetic study of 22 families. J Neurol Neurosurg Psychiatry. 1981;44(10):871–83.View ArticlePubMedPubMed CentralGoogle Scholar
- Fink JK. Hereditary Spastic Paraplegia Overview. In: Pagon RA, Adam MP, Ardinger HH, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K, editors. GeneReviews(R). Seattle: University of Washington; 1993.Google Scholar
- McDermott C, White K, Bushby K, Shaw P. Hereditary spastic paraparesis: a review of new developments. J Neurol Neurosurg Psychiatry. 2000;69(2):150–60.View ArticlePubMedPubMed CentralGoogle Scholar
- Loureiro JL, Brandao E, Ruano L, Brandao AF, Lopes AM, Thieleke-Matos C, Miller-Fleming L, Cruz VT, Barbosa M, Silveira I, ,et al. Autosomal dominant spastic paraplegias: a review of 89 families resulting from a portuguese survey. JAMA Neurol. 2013;70(4):481–7.View ArticlePubMedGoogle Scholar
- Lo Giudice T, Lombardi F, Santorelli FM, Kawarai T, Orlacchio A. Hereditary spastic paraplegia: clinical-genetic characteristics and evolving molecular mechanisms. Exp Neurol. 2014;261:518–39.View ArticlePubMedGoogle Scholar
- Schule R, Schols L. Genetics of hereditary spastic paraplegias. Semin Neurol. 2011;31(5):484–93.View ArticlePubMedGoogle Scholar
- Klebe S, Stevanin G, Depienne C. Clinical and genetic heterogeneity in hereditary spastic paraplegias: From SPG1 to SPG72 and still counting. Rev Neurol. 2015;171(6–7):505–30.View ArticlePubMedGoogle Scholar
- Ruano L, Melo C, Silva MC, Coutinho P. The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies. Neuroepidemiology. 2014;42(3):174–83.View ArticlePubMedGoogle Scholar
- Erichsen AK, Koht J, Stray-Pedersen A, Abdelnoor M, Tallaksen CM. Prevalence of hereditary ataxia and spastic paraplegia in southeast Norway: a population-based study. Brain. 2009;132(Pt 6):1577–88.View ArticlePubMedGoogle Scholar
- Fourtassi M, Jacquin-Courtois S, Scheiber-Nogueira MC, Hajjioui A, Luaute J, Charvier K, Maucort-Boulch D, Rode G. Bladder dysfunction in hereditary spastic paraplegia: a clinical and urodynamic evaluation. Spinal Cord. 2012;50(7):558–62.View ArticlePubMedGoogle Scholar
- Braschinsky M, Zopp I, Kals M, Haldre S, Gross-Paju K. Bladder dysfunction in hereditary spastic paraplegia: what to expect? J Neurol Neurosurg Psychiatry. 2010;81(3):263–6.View ArticlePubMedGoogle Scholar
- Bushman W, Steers WD, Meythaler JM. Voiding dysfunction in patients with spastic paraplegia: urodynamic evaluation and response to continuous intrathecal baclofen. Neurourol Urodyn. 1993;12(2):163–70.View ArticlePubMedGoogle Scholar
- Webb S, Hutchinson M. Cognitive impairment in families with pure autosomal dominant hereditary spastic paraparesis. Brain. 1998;121(Pt 5):923–9.View ArticlePubMedGoogle Scholar
- Byrne PC, Mc Monagle P, Webb S, Fitzgerald B, Parfrey NA, Hutchinson M. Age-related cognitive decline in hereditary spastic paraparesis linked to chromosome 2p. Neurology. 2000;54(7):1510–7.View ArticlePubMedGoogle Scholar
- Murphy S, Gorman G, Beetz C, Byrne P, Dytko M, McMonagle P, Kinsella K, Farrell M, Hutchinson M. Dementia in SPG4 hereditary spastic paraplegia: clinical, genetic, and neuropathologic evidence. Neurology. 2009;73(5):378–84.View ArticlePubMedGoogle Scholar
- Tallaksen CM, Guichart-Gomez E, Verpillat P, Hahn-Barma V, Ruberg M, Fontaine B, Brice A, Dubois B, Durr A. Subtle cognitive impairment but no dementia in patients with spastin mutations. Arch Neurol. 2003;60(8):1113–8.View ArticlePubMedGoogle Scholar
- Matcham F, Scott IC, Rayner L, Hotopf M, Kingsley GH, Norton S, Scott DL, Steer S. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44(2):123–30.View ArticlePubMedGoogle Scholar
- Paulsen JS, Nance M, Kim JI, Carlozzi NE, Panegyres PK, Erwin C, Goh A, McCusker E, Williams JK. A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases. Prog Neurobiol. 2013;110:2–28.View ArticlePubMedGoogle Scholar
- Braschinsky M, Rannikmae K, Krikmann U, Luus SM, Raidvee A, Gross-Paju K, Haldre S. Health-related quality of life in patients with hereditary spastic paraplegia in Estonia. Spinal Cord. 2011;49(2):175–81.View ArticlePubMedGoogle Scholar
- Klimpe S, Schule R, Kassubek J, Otto S, Kohl Z, Klebe S, Klopstock T, Ratzka S, Karle K, Schols L. Disease severity affects quality of life of hereditary spastic paraplegia patients. Eur J Neurol. 2012;19(1):168–71.View ArticlePubMedGoogle Scholar
- Servelhere KR, Faber I, Saute JAM, Moscovich M, D’Abreu A, Jardim LB, Teive HAG, Lopes-Cendes I, Franca Jr MC. Non-motor symptoms in patients with hereditary spastic paraplegia caused by SPG4 mutations. Eur J Neurol. 2016;23(2):408–11.View ArticlePubMedGoogle Scholar
- Cohen J. A power primer. Psychol Bull. 1992;112(1):155–9.View ArticlePubMedGoogle Scholar
- de Bot ST, Burggraaff RC, Herkert JC, Schelhaas HJ, Post B, Diekstra A, van Vliet RO, van der Knaap MS, Kamsteeg EJ, Scheffer H, et al. Rapidly deteriorating course in Dutch hereditary spastic paraplegia type 11 patients. Eur J Hum Genet. 2013;21(11):1312–5.View ArticlePubMedPubMed CentralGoogle Scholar
- Coggrave M, Norton C, Cody JD. Management of faecal incontinence and constipation in adults with central neurological diseases. Cochrane Database Syst Rev 2014, 1 (Art. No.: CD002115).Google Scholar
- Thompson EH, Bennet KM. Measurement of Masculinity Idiologies: A (critical) review. Psychol Men Masculinity. 2015;16(2):115–33.View ArticleGoogle Scholar
- Melchiorre MG, Chiatti C, Lamura G, Torres-Gonzales F, Stankunas M, Lindert J, Ioannidi-Kapolou E, Barros H, Macassa G, Soares J. Social support, socio-economic status, health and abuse among older people in seven European countries. PLoS One. 2013;8(1):e54856.View ArticlePubMedPubMed CentralGoogle Scholar